Femasys’ Third-Quarter 2026 Results Could Not Be Verified From Reliable Sources
Key Facts
Femasys’ third-quarter 2026 results could not be verified from a reliable public source, so its loss per share and revenue, or how they compared with analyst expectations, cannot be confirmed. The Seeking Alpha page attributed as the source of those figures could not be opened, and no third-quarter results announcement appeared on the investor relations page reviewed. The company reported results in August for the quarter ended June 30, its latest confirmed quarterly data in the available information. Femasys said sales for that quarter fell 18.9% year over year to $331,827. The company attributed the decline mainly to lower FemVue sales.
Data for the quarter ended June 30 showed a net loss of $4,469,095, or $1.33 per basic and diluted share, compared with a net loss of $4,585,922, or $3.18 per share, in the same quarter of 2025. The company said the loss per share in both periods was attributable to common stockholders. In the first half of 2026, the net loss was $3,622,995, or $1.08 per share, compared with $10,482,761, or $7.76 per share, in the first half of 2025. On the sales front, first-half revenue rose 0.8% to $756,716 from $750,532 in the comparable period. Femasys attributed the increase mainly to FemaSeed sales, while linking the second-quarter sales decline mainly to lower FemVue sales.
Research and development expenses rose 37.6% to $1,946,878 in the quarter ended June 30, 2026, compared with $1,414,429 in the same period of 2025, the company said. The increase was $532,449, which Femasys attributed mainly to higher clinical costs, along with products in development moving into inventory to support commercialization during 2025. The company said lower compensation costs offset part of the increase. Commenting on the development program, Chief Executive Kathy Lee-Sepsick said August financing allowed the company to "make meaningful progress in the FINALE trial." She added that doubling the study sites "represents important progress in executing our U.S. regulatory strategy."
The company had about $1.4 million in cash and cash equivalents on June 30, 2026, according to its published financial results. After that date, Femasys completed a private placement that brought in about $30 million in gross proceeds in August. The company said the financing enabled it to advance the FINALE trial and linked the increase in study sites to executing its U.S. regulatory strategy. These figures provide financial and operational context for the first-half data, but do not in themselves confirm third-quarter results or the figures attributed to them. The information that could be verified did not include an official third-quarter results announcement or a specific subsequent publication date.